✦ LIBER ✦

Long-term experience with current disease-modifying drugs in multiple sclerosis

✍ Scribed by Corey C. Ford

Publisher: Springer
Year: 2006
Tongue: English
Weight: 321 KB
Volume: 253
Category: Article
ISSN: 0340-5354
DOI: 10.1007/s00415-006-6007-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Postmarketing evidence of disease-modify

Postmarketing evidence of disease-modifying drugs in multiple sclerosis

✍ Maria Trojano; Damiano Paolicelli; Aurora Fuiani; Fabio Pellegrini; Pietro Iaffa 📂 Article 📅 2008 🏛 Springer Milan 🌐 English ⚖ 33 KB

Long-term experience with interferon bet

Long-term experience with interferon beta-1b (Betaferon®) in multiple sclerosis

✍ Barry G. W. Arnason 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 284 KB

Long-term results of immunomodulatory tr

Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience

✍ Angelo Ghezzi; Maria Pia Amato; Pietro Annovazzi; Marco Capobianco; Paolo Gallo; 📂 Article 📅 2009 🏛 Springer Milan 🌐 English ⚖ 297 KB

Reduction in long-term disability in pat

Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug–based treatment strategies

✍ James F. Fries; Catherine A. Williams; Dianne Morfeld; Gurkirpal Singh; John Sib 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 690 KB

Short-term treatment with interferon-α/β

Short-term treatment with interferon-α/β promotes remyelination, whereas long-term treatment aggravates demyelination in a murine model of multiple sclerosis

✍ M. Kariuki Njenga; Michael J. Coenen; Nannette DeCuir; Hung-Yueh Yeh; Moses Rodr 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 346 KB 👁 1 views

The mechanisms by which type I interferons (IFN) reduce the rate and severity of exacerbations in multiple sclerosis are unknown. We utilized a model of multiple sclerosis to determine the extent of demyelination and remyelination in Theiler's murine encephalomyelitis virus (TMEV)infected SJL/J mice

Long-term therapy with cyclosporin A doe

Long-term therapy with cyclosporin A does not influence serum concentrations of vitamin D metabolites in patients with multiple sclerosis

✍ Reichel, H. ;Gr��inger, A. ;Knehans, A. ;K�hn, K. ;Schmidt-Gayk, H. ;Ritz, E. 📂 Article 📅 1992 🏛 Springer-Verlag 🌐 English ⚖ 518 KB